Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-26-022010
Filing Date
2026-05-08
Accepted
2026-05-08 17:01:42
Documents
58
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 543426
2 EX-31.1 ex31-1.htm EX-31.1 8359
3 EX-32.1 ex32-1.htm EX-32.1 4584
4 GRAPHIC form10-q_001.jpg GRAPHIC 7047
  Complete submission text file 0001493152-26-022010.txt   3454292

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE mtnb-20260331.xsd EX-101.SCH 31914
6 XBRL CALCULATION FILE mtnb-20260331_cal.xml EX-101.CAL 44001
7 XBRL DEFINITION FILE mtnb-20260331_def.xml EX-101.DEF 90718
8 XBRL LABEL FILE mtnb-20260331_lab.xml EX-101.LAB 300473
9 XBRL PRESENTATION FILE mtnb-20260331_pre.xml EX-101.PRE 233770
61 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 347243
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

EIN.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38022 | Film No.: 26959503
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)